KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Bionano Genomics (BNGO) Accumulated Depreciation & Amortization (2017 - 2025)

Bionano Genomics' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $14.0 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 2.29% year-over-year to $14.0 million; the TTM value through Dec 2024 reached $14.0 million, up 2.29%, while the annual FY2024 figure was $14.0 million, 2.29% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $14.0 million at Bionano Genomics, up from -$17.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $14.0 million in Q4 2024 and bottomed at -$17.4 million in Q3 2024.
  • The 5-year median for Accumulated Depreciation & Amortization is $6.5 million (2021), against an average of $4.1 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 187.11% in 2022 before it increased 2.29% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.5 million in 2020, then surged by 126.57% to $3.4 million in 2021, then surged by 187.11% to $9.6 million in 2022, then soared by 42.48% to $13.7 million in 2023, then increased by 2.29% to $14.0 million in 2024.
  • Per Business Quant, the three most recent readings for BNGO's Accumulated Depreciation & Amortization are $14.0 million (Q4 2024), -$17.4 million (Q3 2024), and $13.7 million (Q4 2023).